biomodal (Cambridge Epigenetix Limited)
Cambridge Epigenetix’s mission is to harness the power of epigenetics to develop the next generation of diagnostics and therapeutics. . . Epigenetics has the potential to improve human health though the earlier diagnosis, improved patient stratification and the development of more effective, targeted therapies. Importantly, epigenetic modifications are also reversible, allowing physicians to identify and suggest lifestyle changes that are most beneficial for preventing disease. . . We are currently applying our disruptive epigenetics discovery platform and know-how to biomarker and clinical assay development programmes for a number of diseases with significant unmet need — both internally and in partnership with leading biopharma companies.